Nvidia is a multinational technology company established in Delaware and headquartered in California, US. Powered by the GPU program of Nividia, AI technology is capable of emulating systems that build up human intelligence, as well as playing an important role in speeding up the production of the Covid-19 vaccine.

In the past, the cost of developing new pharmaceutical drugs could have been as high as $2.5 billion (doubling every nine years) and 90% of the effort to rush a vaccine to market has been unsuccessful.

Nvidia shortens drugs-making time for the patients while still significantly reducing costs. "COVID-19 hits home this urgency for new tools", said Jensen Huang.

During presentations inside the modern kitchen at home, Huang also introduced an update about the Nvidia Clara Discovery toolkit to help scientists prepare medicines against the disease.

NVIDIA is bringing its AI expertise to bear in the fight against COVID-19, the company announced during GTC 2020 event.

Nvidia Clara is a healthcare application framework for AI-powered imaging, genomics, and for the development and deployment of smart sensors. Nvidia Clara is used to help scientists find breakthroughs throughout the entire COVID-19 spectrum - from detection and containment to mitigation and treatment, to monitoring and tracking.

Dr. Hal Barron, Chief Scientific Officer and President of R&D at GSK commented: “AI and machine learning are like a new microscope that will help scientists to see things that they couldn’t see otherwise. NVIDIA’s investment in computing, combined with the power of deep learning, will enable solutions to some of the life sciences industry’s greatest challenges and help us continue to deliver transformational medicines and vaccines to patients. Together with GSK’s new AI lab in London, I am delighted that these advanced technologies will now be available to help the UK’s outstanding scientists”.

Backed by the Nividia study, researchers use biomedical-specific language models for their work. This means researchers can organize and activate large datasets, research literature, and sort through papers or patents on existing treatments and other vital real-world data.

With such powerful new tools available to scientists, many people are hoping this research can lead to the success of a vaccine within a year or two when they have often taken a decade or longer to create.

Nvidia co-founder Jensen Huang (billionaire Taiwanese - US) introduced AI technology in the modern kitchen at home.

Even in places where technology doesn't exist, Nividia still actively develop innovative tools. Huang added: “Where no tools exist, we develop them - like Nvidia Parabricks, Clara Imaging, BioMegatron, Biobert, Nvidia Rapids”.

“The use of big data, supercomputing, and artificial intelligence have the potential to transform research and development; from target identification through clinical research and all the way to the launch of new medicines,” commented James Weatherall, Ph.D., Head of Data Science and AI at AstraZeneca.

During his keynote, Huang provided more details about Nvidia’s effort to build the UK’s fastest supercomputer - which will be used to further healthcare research - the Cambridge-1.

Nvidia has established partnerships with companies leading the fight against Covid-19 and other viruses including AstraZeneca, GSK, King’s College London, the Guy’s and St Thomas’ NHS Foundation Trust, and startup Oxford Nanopore. These partners can harness Cambridge-1 for their vital research.

Furthermore, Nvidia owns DGX SuperPODs, which is the world's first AI technology turnkey solution to set up its own AI supercomputers for organizations. The solution was developed from years of research for NVIDIA’s own work in healthcare, automotive, healthcare, conversational AI, recommender systems, data science, and computer graphics.

“Tackling the world’s most pressing challenges in healthcare requires massively powerful computing resources to harness the capabilities of AI”, said Huang. “The Cambridge-1 supercomputer will serve as a hub of innovation for the UK and further the groundbreaking work being done by the nation’s researchers in critical healthcare and drug discovery”.

Despite standing in a very beautiful kitchen at home, Huang is eager to return to the big stage for the next GTC event in 2021. In parallel with that, the Covid-19 is expected to be put in a rear-view mirror.

Source: Artificial Intelligence News